Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581636 | 0.92 | PDPK1 (0.43) | RAF1TLK2JAK3CCNB2CDK1 | |
| SCHEMBL3578283 | 0.92 | PIM1 (0.42) | RAF1TLK2ALKRETFLT3 | |
| SCHEMBL3572331 | 0.91 | LMNA (0.45) | RAF1TLK2ALKJAK3RET | |
| SCHEMBL3578693 | 0.89 | JAK3 (0.52) | RAF1TLK2JAK3CCNB2CDK1 | |
| SCHEMBL3578699 | 0.89 | JAK3 (0.52) | RAF1TLK2JAK3CCNB2CDK1 | |
| SCHEMBL3572328 | 0.88 | PDPK1 (0.46) | RAF1TLK2JAK3CCNB2CDK1 | |
| SCHEMBL4757664 | 0.88 | PDPK1 (0.46) | RAF1TLK2JAK3CCNB2CDK1 | |
| SCHEMBL3581212 | 0.87 | NOX4 (0.46) | RAF1TLK2RETAURKANOX4 | |
| SCHEMBL3578279 | 0.85 | TGM2 (0.37) | RAF1TLK2FLT3CCNB2CDK1 | |
| SCHEMBL3581088 | 0.84 | RET (0.40) | ALKRETFLT3IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | RAF1 172/4885TLK2 304/4885ALK 191/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | RAF1 69/4885TLK2 363/4885ALK 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.